Sunfa Cheng

3.1k total citations · 1 hit paper
48 papers, 2.2k citations indexed

About

Sunfa Cheng is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Nephrology. According to data from OpenAlex, Sunfa Cheng has authored 48 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Psychiatry and Mental health, 19 papers in Pathology and Forensic Medicine and 13 papers in Nephrology. Recurrent topics in Sunfa Cheng's work include Migraine and Headache Studies (27 papers), Trigeminal Neuralgia and Treatments (19 papers) and Parathyroid Disorders and Treatments (11 papers). Sunfa Cheng is often cited by papers focused on Migraine and Headache Studies (27 papers), Trigeminal Neuralgia and Treatments (19 papers) and Parathyroid Disorders and Treatments (11 papers). Sunfa Cheng collaborates with scholars based in United States, Germany and United Kingdom. Sunfa Cheng's co-authors include Daniel D. Mikol, Uwe Reuter, Messoud Ashina, Stewart J. Tepper, Robert Lenz, Lulu Ren Sterling, Munro Peacock, Dolores Shoback, David W. Dodick and Stephen D. Silberstein and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Sunfa Cheng

44 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure

2013 400 citations Karl Swedberg, James B. Young et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sunfa Cheng United States	21	1.1k	913	596	441	300	48	2.2k
Harald Heidecke Germany	22	367 0.3×	353 0.4×	171 0.3×	118 0.3×	313 1.0×	88	2.2k
Tae-Jin Song South Korea	25	433 0.4×	265 0.3×	80 0.1×	271 0.6×	334 1.1×	71	1.7k
Jianzhao Xu United States	23	197 0.2×	161 0.2×	256 0.4×	288 0.7×	375 1.3×	62	1.6k
Naoki Ikegaya Japan	19	140 0.1×	99 0.1×	388 0.7×	211 0.5×	135 0.5×	90	1.2k
Michiel J. Bos Netherlands	15	217 0.2×	188 0.2×	455 0.8×	108 0.2×	367 1.2×	22	1.6k
Thorsten Reffelmann Germany	27	139 0.1×	385 0.4×	117 0.2×	163 0.4×	1.2k 3.9×	60	2.3k
Alexander Ovechkin United States	23	86 0.1×	496 0.5×	36 0.1×	229 0.5×	292 1.0×	52	1.6k
Young Chul Yoo South Korea	23	188 0.2×	89 0.1×	124 0.2×	66 0.1×	368 1.2×	78	1.4k
Olusegun A. Mojiminiyi Kuwait	25	56 0.1×	220 0.2×	68 0.1×	461 1.0×	161 0.5×	74	1.6k

Countries citing papers authored by Sunfa Cheng

Since Specialization

Citations

This map shows the geographic impact of Sunfa Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sunfa Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sunfa Cheng more than expected).

Fields of papers citing papers by Sunfa Cheng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sunfa Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sunfa Cheng. The network helps show where Sunfa Cheng may publish in the future.

Co-authorship network of co-authors of Sunfa Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Sunfa Cheng. A scholar is included among the top collaborators of Sunfa Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sunfa Cheng. Sunfa Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tepper, Stewart J., Richard B. Lipton, Stephen D. Silberstein, et al.. (2023). Long‐term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache The Journal of Head and Face Pain. 63(6). 730–742. 5 indexed citations

Girard, N., K. Park, Kun Tang, et al.. (2023). LBA5 Amivantamab plus chemotherapy vs chemotherapy as first-line treatment in EGFR Exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): Primary results from PAPILLON, a randomized phase III global study. Annals of Oncology. 34. S1304–S1304. 5 indexed citations

Hirata, Koichi, Takao Takeshima, Fumihiko Sakai, et al.. (2023). Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. BMJ Open. 13(8). e068616–e068616.

Karaboyas, Angelo, Daniel G. Muenz, Yunji Hwang, et al.. (2022). Etelcalcetide Versus Cinacalcet in Hemodialysis Patients in the United States: A Facility Calcimimetic Approach to Assess Real-World Effectiveness. Kidney Medicine. 4(6). 100475–100475. 5 indexed citations

Xing, Changying, Jing Chen, Li Zuo, et al.. (2021). A Phase I, Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Etelcalcetide Administered Intravenously to Chinese Patients With Chronic Kidney Disease Undergoing Hemodialysis. Clinical Therapeutics. 43(11). 2013–2023. 1 indexed citations

Tepper, Stewart J., Messoud Ashina, Uwe Reuter, et al.. (2021). Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. The Journal of Headache and Pain. 22(1). 81–81. 11 indexed citations

Hirata, Koichi, Fumihiko Sakai, Takao Takeshima, et al.. (2021). Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial. The Journal of Headache and Pain. 22(1). 110–110. 13 indexed citations

Ashina, Messoud, Peter J. Goadsby, Uwe Reuter, et al.. (2020). Sustained Efficacy and Long-term Safety of Erenumab in Patients with Episodic Migraine: 4+ Year Results of a 5-year, Open-label Treatment Period (1203). Neurology. 94(15_supplement). 5 indexed citations

Lipton, Richard B., Stewart J. Tepper, Stephen D. Silberstein, et al.. (2020). Reversion from chronic migraine to episodic migraine following treatment with erenumab: Results of a post-hoc analysis of a randomized, 12-week, double-blind study and a 52-week, open-label extension. Cephalalgia. 41(1). 6–16. 25 indexed citations

10.

Bushinsky, David A., Glenn M. Chertow, Sunfa Cheng, et al.. (2019). One-year safety and efficacy of intravenous etelcalcetide in patients on hemodialysis with secondary hyperparathyroidism. Nephrology Dialysis Transplantation. 35(10). 1769–1778. 24 indexed citations

11.

Tepper, Stewart J., Messoud Ashina, Uwe Reuter, et al.. (2019). Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine (P1.10-016). Neurology. 92(15_supplement).

12.

Winner, Paul, Uwe Reuter, David W. Dodick, et al.. (2018). Erenumab Safety Among Migraine Patients Using Triptans or With Cardiovascular (CV) Risk Factors (P4.100). Neurology. 90(15_supplement). 1 indexed citations

13.

Schwedt, Todd J., Uwe Reuter, Stewart J. Tepper, et al.. (2018). Early onset of efficacy with erenumab in patients with episodic and chronic migraine. The Journal of Headache and Pain. 19(1). 92–92. 72 indexed citations

14.

Welsh, Paul, Lei Kou, Changhong Yu, et al.. (2017). Prognostic Importance of Emerging Cardiac, Inflammatory, and Renal Biomarkers in Chronic Heart Failure Patients with Reduced Ejection Fraction and Anaemia: RED-HF Study. European Journal of Heart Failure. 20(2). 268–277. 41 indexed citations

15.

Tepper, Stewart J., Richard B. Lipton, Uwe Reuter, et al.. (2017). Patient-Reported Outcomes in Patients with Chronic Migraine Receiving Placebo or Erenumab (AMG 334) in a Phase 2, Randomized, Double-Blind Study (P2.167). Neurology. 88(16_supplement). 2 indexed citations

16.

McMurray, John J.V., Inder S. Anand, Rafael Díaz, et al.. (2013). Baseline Characteristics of Patients in the Reduction of Events with Darbepoetin Alfa in Heart Failure Trial (RED-HF). European Journal of Heart Failure. 15(3). 334–341. 23 indexed citations

17.

Swedberg, Karl, James B. Young, Inder S. Anand, et al.. (2013). Treatment of Anemia with Darbepoetin Alfa in Systolic Heart Failure. New England Journal of Medicine. 368(13). 1210–1219. 400 indexed citations breakdown →

18.

Reed, Shelby D., Stephen J. Ellis, John J. Isitt, et al.. (2012). Associations Between Hemoglobin Level, Resource Use, and Medical Costs in Patients With Heart Failure: Findings From HF-ACTION. Journal of Cardiac Failure. 18(10). 784–791. 5 indexed citations

19.

Peacock, Munro, John P. Bilezikian, Michael A. Bolognese, et al.. (2010). Cinacalcet HCl Reduces Hypercalcemia in Primary Hyperparathyroidism across a Wide Spectrum of Disease Severity. The Journal of Clinical Endocrinology & Metabolism. 96(1). E9–E18. 71 indexed citations

20.

Marlin, G. E. & Sunfa Cheng. (1979). Pharmacokinetics and tolerability of a single oral 600-mg dose of doxycycline.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 1(12). 575–6. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact